Invention Grant
- Patent Title: Salts of Dasatinib in crystalline form
- Patent Title (中): 达沙替尼盐结晶
-
Application No.: US14907148Application Date: 2014-07-22
-
Publication No.: US09556164B2Publication Date: 2017-01-31
- Inventor: Andreas Hafner , Fritz Blatter , Martin Szelagiewicz , Bernd Siebenhaar , Tiziana Chiodo , Tobias Hintermann , Beate Salvador , Marcus Vossen
- Applicant: BASF SE
- Applicant Address: DE
- Assignee: BASF SE
- Current Assignee: BASF SE
- Current Assignee Address: DE
- Agency: Drinker Biddle & Reath LLP
- Priority: EP13178021 20130725
- International Application: PCT/EP2014/065675 WO 20140722
- International Announcement: WO2015/011120 WO 20150129
- Main IPC: C07D417/12
- IPC: C07D417/12 ; C07D275/06
Abstract:
The present invention primarily relates to molecular crystalline substances, preferably salts of Dasatinib in crystalline form, comprising a compound of formula 1, preferably a cation of a compound of formula 1, and a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin, preferably an anion thereof. The invention is further related to pharmaceutical compositions comprising such a substance. Furthermore, the invention relates to processes for preparing said substances. The invention also relates to several aspects of using said substances or pharmaceutical compositions to treat a disease.
Public/Granted literature
- US20160168143A1 SALTS OF DASATINIB IN CRYSTALLINE FORM Public/Granted day:2016-06-16
Information query
